Loading...
•
Mar 31, 2023
Edwards Lifesciences Q1 2023 Earnings Report
Reported financial results for the quarter ended March 31, 2023.
Key Takeaways
Edwards Lifesciences reported a strong start to 2023, exceeding expectations with Q1 sales growing 9% to $1.46 billion and adjusted EPS of $0.62. The company raised its full-year sales guidance and expects a return to higher sales growth, driven by its patient-focused innovation strategy.
Q1 sales grew 9 percent to $1.46 billion; constant currency sales grew 13 percent.
Q1 TAVR sales grew 8 percent; constant currency sales grew 11 percent.
Q1 EPS of $0.56; adjusted EPS of $0.62.
Raised full year 2023 sales guidance.
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
The company is raising its full year sales guidance for all product groups. Full year 2023 sales are expected to grow 10 to 12 percent. For the second quarter of 2023, the company projects total sales to be between $1.48 and $1.56 billion, and adjusted EPS of $0.62 to $0.68.
Positive Outlook
- Full year 2023 sales are expected to grow 10 to 12 percent.
- TAVR sales of $3.8 to $4.0 billion.
- TMTT sales of $170 to $200 million.
- Critical Care sales of $870 to $940 million.
- Surgical Structural Heart sales at the high end of its $870 to $970 million range.
Revenue & Expenses
Visualization of income flow from segment revenue to net income